2024
Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors
Costa P, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Coelho P, Campoverde L, Hardy N, Bialick S, Freire A, D’Amato G, Chang Y, Mesenger J, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors. Cancer 2024 PMID: 39543805, DOI: 10.1002/cncr.35647.Peer-Reviewed Original ResearchProgression-free survivalAnthracycline-containing regimensAnthracycline-based therapyDesmoid tumorsAdverse eventsOne-year progression-free survivalMulti-institutional retrospective analysisAnthracycline-containing regimenCommon grade 1Desmoid tumor patientsGrade 3 eventsAnthracycline-based chemotherapyHand-foot syndromeSecondary end pointsActivity of sorafenibProgressive desmoid tumorsYear of treatmentMedian TTRBaseline characteristicsTumor patientsLocal invasionTreatment responseSorafenibAnthracyclinesEnd pointsGeneral versus disease-specific medical oncology consults and impact on inpatient quality of care.
Prsic E, Deshpande H, Wei W, Strait M, Chiang A. General versus disease-specific medical oncology consults and impact on inpatient quality of care. Journal Of Clinical Oncology 2024, 20: 321-321. DOI: 10.1200/op.2024.20.10_suppl.321.Peer-Reviewed Original ResearchAdvanced practice providersInpatient qualityPost-interventionOncology consultationICU rateEmergency departmentInpatient quality of careQuality of careHospice referral ratesMedical oncology consultationHospice referralOutpatient productionPractice providersLevel of satisfactionClinician satisfactionConsultative carePre-interventionReferral ratesED visitsSurveys pre-Clinician experienceGeneral consultationVisit dataConsultation modelReadmission ratesUse of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma.
Wu H, Sukhanova M, Tang H, Lu X, Zhong M, Deshpande H, Pollack S, Laskin W, Alexiev B. Use of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma. Archives Of Pathology & Laboratory Medicine 2024 PMID: 39164013, DOI: 10.5858/arpa.2024-0098-oa.Peer-Reviewed Original ResearchAtypical lipomatous tumor/well-differentiated liposarcomaMDM2-amplified liposarcomasDedifferentiated componentDedifferentiated liposarcomaAdverse eventsMitotic countLocal recurrence statusMDM2 copy numberAssociated with adverse eventsLog-rank testOverall tumor volumeUnivariate logistic regressionChromosome 12q13-15Statistically significant associationPercentage of cellsTumor dimensionTumor volumeTumor sizeMDM2 proto-oncogeneClinicopathological characteristicsPathology reportsGrade 3Recurrence statusUnivariate analysisMultivariate regression modelPhase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC).
Sehgal K, Shi R, Pappa T, Min J, Oakley L, ONeill A, Dennis M, Deshpande H, Haddad R, Lorch J. Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC). Journal Of Clinical Oncology 2024, 42: 6109-6109. DOI: 10.1200/jco.2024.42.16_suppl.6109.Peer-Reviewed Original ResearchMetastatic medullary thyroid carcinomaTreatment-related adverse eventsProgression-free survivalRAIR-DTCProgression-freeOverall survivalClinical trialsMedian progression-free survivalCycle 2 onwardsMedian overall survivalPhase II clinical trialMedullary thyroid carcinomaPhase II trialMulti-kinase inhibitorII clinical trialsSimon's two-stage designRECIST v1.1Systemic therapyTolerated doseStage 2Thyroid carcinomaMedian agePlanned escalationTherapeutic optionsInhibitor exposureAn Unexpected Finding: A Progressive Case of Thoracic Sarcoma
Montalvo Campana M, Paredes Mogica J, Laskin W, Deshpande H. An Unexpected Finding: A Progressive Case of Thoracic Sarcoma. 2024, a6534-a6534. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6534.Peer-Reviewed Original ResearchA Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.
Schuetze S, Ballman K, Heise R, Ganjoo K, Davis E, George S, Burgess M, Choy E, Shepard D, Tinoco G, Hirbe A, Kelly C, Attia S, Deshpande H, Schwartz G, Siontis B, Riedel R, von Mehren M, Kozlowski E, Chen H, Astbury C, Rubin B. A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma. Clinical Cancer Research 2024, 30: 4584-4592. PMID: 38446990, PMCID: PMC11377863, DOI: 10.1158/1078-0432.ccr-23-3817.Peer-Reviewed Original ResearchEpithelioid hemangioendotheliomaMetastatic epithelioid hemangioendotheliomaMedian PFSOS ratesEvidence of tumor progressionPhase 2 trialMedian pain intensityEffects of trametinibMAPK pathwayActivation of MAPK pathwayInhibitor of MEKPalliative benefitPain intensityPain scoresPrimary endpointAssociated with reductionsTrametinibTumor progressionTumor samplesOncogenic driversVascular cancerPatientsPatient safetyResponse ratePFS
2023
Atezolizumab for Advanced Alveolar Soft Part Sarcoma
Chen A, Sharon E, O'Sullivan-Coyne G, Moore N, Foster J, Hu J, Van Tine B, Conley A, Read W, Riedel R, Burgess M, Glod J, Davis E, Merriam P, Naqash A, Fino K, Miller B, Wilsker D, Begum A, Ferry-Galow K, Deshpande H, Schwartz G, Ladle B, Okuno S, Beck J, Chen J, Takebe N, Fogli L, Rosenberger C, Parchment R, Doroshow J. Atezolizumab for Advanced Alveolar Soft Part Sarcoma. New England Journal Of Medicine 2023, 389: 911-921. PMID: 37672694, PMCID: PMC10729808, DOI: 10.1056/nejmoa2303383.Peer-Reviewed Original ResearchConceptsAdvanced alveolar soft part sarcomaAlveolar soft part sarcomaProgression-free survivalSoft part sarcomaObjective responsePart sarcomaMedian progression-free survivalTreatment-related grade 4Rare soft tissue sarcomaData cutoff dateImmune checkpoint inhibitorsPhase 2 studyResponse Evaluation CriteriaThird of patientsDuration of responseSoft tissue sarcomasYears of treatmentCheckpoint inhibitorsAdverse eventsMedian durationPartial responseComplete responseDeath-1PD-L1Pediatric patients
2022
Neurogenic orthostatic hypotension after treatment with sorafenib
Wippel C, Deshpande H, Patwa H, Peixoto A. Neurogenic orthostatic hypotension after treatment with sorafenib. BMJ Case Reports 2022, 15: e247140. PMID: 36549761, PMCID: PMC9791444, DOI: 10.1136/bcr-2021-247140.Peer-Reviewed Original ResearchConceptsOrthostatic hypotensionVascular endothelial growth factor inhibitorsLower extremity weaknessNeurogenic orthostatic hypotensionPalpable abdominal massGrowth factor inhibitorsHistory of fatigueAppropriate chronotropic responseSupine hypertensionAbdominal painAutonomic testingExtremity weaknessAbdominal massSodium intakeChronotropic responseFactor inhibitorsCompression stockingsDesmoid tumorsLiberal fluidsSympathetic responseHypotensionTumor growthSorafenibGradual improvementTreatmentHemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma
Kenworthy C, Di M, Deshpande H. Hemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma. Current Problems In Cancer Case Reports 2022, 8: 100202. DOI: 10.1016/j.cpccr.2022.100202.Peer-Reviewed Original ResearchNatural killer (NK) cell activityImmune checkpoint inhibitor therapyImmune checkpoint inhibitor useSoluble IL-2 receptorCheckpoint inhibitor useImmune checkpoint inhibitorsCheckpoint inhibitor therapyCoffee-ground emesisIL-2 receptorPelvic osteosarcomaCheckpoint inhibitorsElevated ferritinInhibitor therapyHemophagocytic lymphohistiocytosisMetastatic sarcomaFailed treatmentElevated triglyceridesInhibitor useSarcoma patientsConventional therapyCell activationCancer treatmentPatientsSarcomaTherapyAssociation Between Postdischarge Medical Oncology Follow-Up Appointments and Downstream Health Care Use: A Single-Institution Experience
Xiang J, Chow R, Reynoso A, Carafeno T, Deshpande H, Strait M, Prsic E. Association Between Postdischarge Medical Oncology Follow-Up Appointments and Downstream Health Care Use: A Single-Institution Experience. JCO Oncology Practice 2022, 18: e1466-e1474. PMID: 35696632, DOI: 10.1200/op.21.00868.Peer-Reviewed Original ResearchConceptsHealth care useED visitsCare useOncology appointmentsAppointment timingPropensity score-matched analysisMultivariable logistic regression modelYale-New Haven HospitalRetrospective cohort studySingle institution experienceEmergency department visitsTertiary academic centerNew Haven HospitalLower ratesLogistic regression modelsOncology admissionsOncology followCause readmissionMost admissionsCohort studyDepartment visitsMedical oncologySubgroup analysisReadmissionAcademic centersEfficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients
Forman R, Deshpande H, Burtness B, Bhatia AK. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients. Head & Neck 2022, 44: 1777-1786. PMID: 35488876, DOI: 10.1002/hed.27077.Peer-Reviewed Original ResearchConceptsRECIST response rateProgression-free survivalMetastatic/recurrent diseaseOverall survivalInduction chemotherapyRecurrent diseaseNeck cancerMetastatic/recurrent headPFS/overall survivalMean progression-free survivalSuccessful induction rateMean overall survivalPercent of patientsCases of metastasisFrail subsetWeekly paclitaxelFrail patientsAdult patientsElderly patientsPerformance statusRecurrent headInduction cohortInduction groupPatientsRecurrent groupSelinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Morales C, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gröschel S, Hatcher H, Duffaud F, Herráez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Götze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. Journal Of Clinical Oncology 2022, 40: 2479-2490. PMID: 35394800, PMCID: PMC9467680, DOI: 10.1200/jco.21.01829.Peer-Reviewed Original ResearchConceptsProgression-free survivalDedifferentiated liposarcomaNext treatmentCommon treatment-emergent adverse eventsPatients age 12 yearsTreatment-emergent adverse eventsLonger progression-free survivalPlacebo-controlled studyPrimary end pointLines of therapyAge 12 yearsAdverse eventsOverall survivalPlacebo armSupportive careClinical benefitStudy treatmentPredictive biomarkersPreclinical modelsProspective validationGrade 3Dose reductionPlaceboSide effectsPatients
2021
Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma
Hasan NM, Sharma A, Ruzgar NM, Deshpande H, Olino K, Khan S, Ahuja N. Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma. Oncotarget 2021, 12: 1566-1579. PMID: 34381562, PMCID: PMC8351604, DOI: 10.18632/oncotarget.28032.Peer-Reviewed Original ResearchDNA methylationGene expressionSubtype-specific gene expressionDifferential DNA methylationGene expression patternsPromoter CpG islandsRNA-seq dataEpigenetic regulationEpigenetic profilingEpigenetic signaturesCpG islandsEpigenetic alterationsExpression patternsGenesMethylationUnsupervised hierarchical clusteringPotential therapeutic targetMolecular landscapeIntegrated analysisMain clustersPotential targetTherapeutic targetExpressionSubtype-specific differencesMultiple aspectsP10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).
Schuetze S, Ballman K, Ganjoo K, Davis E, Morgan J, Tinoco G, Burgess M, Van Tine B, Choy E, Shepard D, Kelly C, Riedel R, von Mehren M, Siontis B, Attia S, Schwartz G, Deshpande H, Kozlowski E, Chen H, Rubin B. P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE). Journal Of Clinical Oncology 2021, 39: 11503-11503. DOI: 10.1200/jco.2021.39.15_suppl.11503.Peer-Reviewed Original ResearchObjective response ratePhase 2 trialEpithelioid hemangioendotheliomaObjective responseLarge prospective clinical studiesGI adverse effectsMetastatic epithelioid hemangioendotheliomaObjective tumor progressionPrimary trial endpointNausea/vomitingWeeks of therapyBiomarkers of inflammationProspective clinical studyTreatment of patientsClinical Trials NetworkCommon AEsMedian PFSOS ratesPt ageStable diseasePain scoresAdverse eventsMetastatic diseasePain intensityIndolent growthRenal sarcomas: Epidemiology, treatment and outcomes.
Uhlig J, Uhlig A, Deshpande H, Hurwitz M, Humphrey P, Kim K. Renal sarcomas: Epidemiology, treatment and outcomes. Journal Of Clinical Oncology 2021, 39: 362-362. DOI: 10.1200/jco.2021.39.6_suppl.362.Peer-Reviewed Original ResearchPrimitive neuroectodermal tumorRenal sarcomaOverall survivalMalignant rhabdoid tumorSEER databaseSurgical resectionSystemic therapyDistant metastasisTumor diameterSarcoma subtypesIncidence rateRenal malignancyAge-adjusted incidence ratesCox proportional hazards modelMedian tumor diameterAdvanced T stageDifferent histological subtypesProportional hazards modelSolitary fibrous tumorWorse OSAdult patientsFemale predominanceMale predominanceMedian ageOS rates
2018
Predictors of Lymph Node Involvement by Soft Tissue Sarcoma: An Analysis of the National Cancer Database (NCDB)
Miccio J, Jairam V, Gao S, Augustyn A, Oladeru O, Onderdonk B, Costa J, Han D, Khan S, Friedlaender G, Lindskog D, Deshpande H, Tara H, Osborn H, Roberts K, Patel K. Predictors of Lymph Node Involvement by Soft Tissue Sarcoma: An Analysis of the National Cancer Database (NCDB). International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e335. DOI: 10.1016/j.ijrobp.2018.07.1028.Peer-Reviewed Original ResearchAn update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E, Deshpande H, Stein S. An update of lanreotide acetate for treatment of adults with carcinoid syndrome. Drugs Of Today 2018, 54: 457-465. PMID: 30209440, DOI: 10.1358/dot.2018.54.8.2834461.Peer-Reviewed Original ResearchConceptsSymptoms of carcinoid syndromeCarcinoid syndromeCarcinoid tumorsOrigin of carcinoid tumorsTreatment of carcinoid syndromeUrinary 5-hydroxyindoleacetic acidAdvanced metastatic diseaseSomatostatin analogue octreotideTreatment of adultsMetastatic diseaseSerotonin metaboliteAnalogue octreotideNative somatostatinDebilitating diarrheaLanreotide acetateSyndromeTumorSymptom controlLanreotideSlow-growingSymptomsSomatostatinTreatmentHalf-lifeChemotherapyHypothyroidism to predict for long term survival in patients with fosbretabulin treated anaplastic thyroid carcinoma.
Doroshow D, Deshpande H, Remick S, Bhatia A. Hypothyroidism to predict for long term survival in patients with fosbretabulin treated anaplastic thyroid carcinoma. Journal Of Clinical Oncology 2018, 36: e18108-e18108. DOI: 10.1200/jco.2018.36.15_suppl.e18108.Peer-Reviewed Original ResearchEstablishment of a medical student elective on the oncology consult service using the seven principles of teaching.
Deshpande H, Stein S. Establishment of a medical student elective on the oncology consult service using the seven principles of teaching. Journal Of Clinical Oncology 2018, 36: tps11021-tps11021. DOI: 10.1200/jco.2018.36.15_suppl.tps11021.Peer-Reviewed Original ResearchPhase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).
Gounder M, Mahoney M, Van Tine B, Ravi V, Attia S, Deshpande H, Gupta A, Milhem M, Conry R, Movva S, Pishvaian M, Crawford J, Sabagh T, Maki R, Tap W, Lefkowitz R, Agaram N, Wright J, Dueck A, Schwartz G. Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105). Journal Of Clinical Oncology 2018, 36: 11500-11500. DOI: 10.1200/jco.2018.36.15_suppl.11500.Peer-Reviewed Original Research